![]() ![]() Known, suspected, or history of breast cancer except in appropriately selected patients being treated for metastatic disease Reactions have included angioedema and anaphylaxis Hypersensitivity to teriparatide or to any of its excipients Teriparatide (recombinant human parathyroid hormone1-34 Forteo) Pregnancy, women who may become pregnant, and breastfeeding mothersĪllergy to calcitonin-salmon or synthetic calcitonin-salmon Hypersensitivity to zoledronic acid or any components of this product Risedronate/calcium carbonate (Actonel with calcium)ģ5 mg per week (day 1) plus 1,250 mg calcium for no-risedronate days (days 2 through 7 of seven-day treatment cycle)Ĭreatinine clearance < 35 mL per minute per 1.73 m 2 (0.58 mL per second per m 2) and acute renal impairment Patients at increased risk of aspiration should not receive alendronate solutionġ0 mg per day or 70 mg per week, tablet or solutionĪlendronate/cholecalciferol (Fosamax Plus D)ħ0 mg plus 2,800 IU per week 70 mg plus 5,600 IU per weekĥ mg per day 35 mg per week 75 mg in two consecutive days per month 150 mg per month Hypersensitivity to any component of this product Inability to stand or sit upright for at least 30 minutes Medications for preventing and treating postmenopausal osteoporosis are listed in Tables 1 and 2.īisphosphonates (oral unless otherwise specified)ĥ mg per day or 35 mg per week, tablet or solution Hormone therapy (i.e., estrogen or combined estrogen/progestogen) positively affects bone health it is approved for use in women with an increased risk of osteoporosis and fracture. Whether there should be a limit to the duration of bisphosphonate therapy is unknown however, there appears to be a trend toward interrupting therapy after five to 10 years. ![]() Typically, combination therapy is not recommended. ![]() ![]() Calcitonin has weaker data compared with other options therefore, it should be used only in women with less serious osteoporosis who cannot tolerate other treatments. Teriparatide (Forteo) is typically only used in women with severe osteoporosis or who have had fractures. Raloxifene (Evista) can be a good initial treatment in younger postmenopausal women, and denosumab is an option for women with a high risk of fracture. First-line therapy usually consists of bisphosphonates selection should be based on patient preference. ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |